Key statistics dashboard for Annovis Bio, Inc. (ANVS). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases.
Stock Data
| Price | $1.04 |
| Market Cap | $44M |
| Beta | 1.36 |
| Exchange | NYSE |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.58 |
| Price / Book | -9.17 |
| P/S | 0.00 |
| P/FCF | -1.02 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 2.95 |
| Quick Ratio | 2.95 |
| Cash Ratio | 2.95 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | -31.16 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -4.44 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | -0.11 |
| Cash per share | 0.50 |
| FCF per share | -1.16 |
| Tangible Book Value per share | -0.11 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (1-5) | 0.75 |
Related companies: ATNM · BCAB · BTAI · CELU · ELUT · EVAX · MAIA
Explore sector: Healthcare · Biotechnology
More sections of ANVS: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks